Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

Table 2

Reported adverse events severity according to trial arm. All adverse events reported throughout the study according to severity.

	EFV600	EFV800	Total	Test statistics	P value
Total	162	160	322	Chi square (3 df) = 2.47	0.48
Grade 1	75 (46.3%)	61 (38.1%)	136 (42.2%)
Grade 2	54 (33.3%)	58 (36.2%)	112 (34.8%)
Grade 3	20 (12.3%)	24 (15.0%)	44 (13.7%)
Grade 4	13 (8.0%)	17 (10.6%)	30 (9.3%)